Livedoid Vasculopathy When Anticoagulant Therapy Fails to Achieve Rapid Pain Relief
This protocol applies to patients with livedoid vasculopathy (LV) who have not achieved adequate pain control on anticoagulant therapy and whose condition is considered treatment-refractory, warranting escalation to a next-line approach.
Previous treatment — escalation trigger
The preceding regimen involved oral anticoagulants — rivaroxaban, apixaban, edoxaban, or dabigatran. Escalation to this protocol is indicated when rapid pain relief has not been achieved on that regimen.
Next-line approach (partial overview)
For treatment-refractory LV, an intravenous immunoglobulin-based intervention is used — the full regimen structure, dosing framework, and administration schedule are available in the complete protocol.
Goal: significant pain relief
References
DOI: 10.1111/ddg.14520
- IVIG treatment is recommended in treatment-refractory LV (off label).
- The authors recommend a dose of 2 g/kg BW which may be split into several doses and administered over a period of 2–5 days (off label).
- Monshi et al. reported significant pain relief and an increase in DLQI after only six treatment cycles.
View source ↗